Sruthi Vellanki

Sourced from institutional research profiles (UAMS TRI or ARA).

Assistant Professor

UAMS

Faculty Researcher

COM | Internal Med Hem-Onc

4 h-index 37 pubs 52 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Sruthi Vellanki's research focuses on hematology and oncology, with specific interests in multiple myeloma and related blood cancers. She investigates treatment strategies and disease mechanisms, aiming to improve patient outcomes. Her work contributes to the understanding and management of these complex conditions within the field of internal medicine.

Metrics

h-index: 4
Publications: 37
Citations: 52

Selected Publications

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Cardiovascular Autonomic Dysfunction in Cancer Therapy: Clinical Manifestations and Management (2026)

Cardiology Research DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
26-A-9693-ACC PREDICTION OF 1-YEAR MAJOR ADVERSE CARDIAC EVENTS IN CAR-T RECIPIENTS USING RISK SCORE MODELING: EXPANDED WHOLE-COHORT ANALYSIS (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-A-11133-ACC CYTOKINE RELEASE SYNDROME-GUIDED RISK MODELS REDEFINE CARDIOTOXICITY SURVEILLANCE: OPTIMIZING DETECTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION AND ADVERSE CARDIOVASCULAR EVENTS AFTER CAR-T THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)

Journal of the American Society of Nephrology DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 6 citations DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

Journal of Clinical Oncology DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

Blood Cancer Journal 32 citations DOI OpenAlex
PREDICTORS OF ADVERSE CARDIOVASCULAR EVENTS AFTER CHIMERIC ANTIGEN T-CELL (CAR-T) THERAPY (2025)

Journal of the American College of Cardiology DOI OpenAlex
Demographic analysis of survival trends in squamous cell carcinoma of the upper 1/3 of the esophagus: a population-based study (2024)

Diseases of the Esophagus DOI OpenAlex
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)

Blood DOI OpenAlex